All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type
Zachary S Wallace1,2,3,4, Xiaoqing Fu1,2,3, Tyler Harkness1,2,3
1Clinical Epidemiology Program, Mongan Institute.
Insights
Premature mortality in ANCA-associated vasculitis is linked to cardiovascular disease, infection, and malignancy. Patients with MPO-ANCA have a higher risk of cardiovascular death compared to PR3-ANCA patients.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases characterized by inflammation of small blood vessels.
- Understanding the causes of premature mortality in AAV is crucial for improving patient outcomes.
- Stratifying mortality by ANCA type (MPO-ANCA vs. PR3-ANCA) may reveal distinct risk profiles.
Purpose of the Study:
- To investigate the causes of death in a contemporary cohort of patients diagnosed with ANCA-associated vasculitis.
- To analyze mortality patterns based on the specific type of anti-neutrophil cytoplasmic antibody (ANCA) detected.
Main Methods:
- A consecutive inception cohort of AAV patients diagnosed between 2002 and 2017 was identified.
- Vital status was determined using the National Death Index, and mortality incidence was calculated.
- Standardized mortality ratios (SMRs) were compared to the general population, and Cox regression analyzed MPO-ANCA vs. PR3-ANCA cases.
Main Results:
- The cohort comprised 484 patients; 130 deaths occurred over 3385 person-years, resulting in an SMR of 2.3.
- Cardiovascular disease (CVD), malignancy, and infection were the leading causes of death.
- Infection posed the greatest excess mortality risk for both MPO-ANCA and PR3-ANCA patients, while MPO-ANCA patients showed a higher risk of CVD death.
Conclusions:
- Premature mortality in AAV is primarily attributed to CVD, infection, malignancy, and renal disease.
- Infection represents the most significant excess mortality risk, particularly in MPO-ANCA and PR3-ANCA patients.
- MPO-ANCA patients face a substantially higher risk of cardiovascular death compared to PR3-ANCA patients.
Objective:
The objective of this study was to evaluate causes of death in a contemporary inception cohort of ANCA-associated vasculitis patients, stratifying the analysis according to ANCA type.
Methods:
We identified a consecutive inception cohort of patients newly diagnosed with ANCA-associated vasculitis from 2002 to 2017 in the Partners HealthCare System and determined vital status through the National Death Index. We determined cumulative mortality incidence and standardized mortality ratios (SMRs) compared with the general population. We compared MPO- and PR3-ANCA+ cases using Cox regression models.
Results:
The cohort included 484 patients with a mean diagnosis age of 58 years; 40% were male, 65% were MPO-ANCA+, and 65% had renal involvement. During 3385 person-years (PY) of follow-up, 130 patients died, yielding a mortality rate of 38.4/1000 PY and a SMR of 2.3 (95% CI: 1.9, 2.8). The most common causes of death were cardiovascular disease (CVD; cumulative incidence 7.1%), malignancy (5.9%) and infection (4.1%). The SMR for infection was greatest for both MPO- and PR3-ANCA+ patients (16.4 and 6.5). MPO-ANCA+ patients had an elevated SMR for CVD (3.0), respiratory disease (2.4) and renal disease (4.5). PR3- and MPO-ANCA+ patients had an elevated SMR for malignancy (3.7 and 2.7). Compared with PR3-ANCA+ patients, MPO-ANCA+ patients had a higher risk of CVD death [hazard ratio 5.0 (95% CI: 1.2, 21.2]; P = 0.03].
Conclusion:
Premature ANCA-associated vasculitis mortality is explained by CVD, infection, malignancy, and renal death. CVD is the most common cause of death, but the largest excess mortality risk in PR3- and MPO-ANCA+ patients is associated with infection. MPO-ANCA+ patients are at higher risk of CVD death than PR3-ANCA+ patients.
More Related Videos
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm I: Introduction
Coronary Artery Disease I: Introduction
Inflammation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests


